EGFR and cancer: As in many other types of cancer, also in HNSCC, selective Epidermal Growth Factor Receptor (EGFR) inhibitors (gefitinib and erlotinib) and EGFR antibodies (cetuximab) have demonstrated significant antitumor activity in vitro and in vivo4.